BUSINESS
Takeda’s Specialty Biz Unit Most Likely to Handle GI Meds, Entyvio Launch Apparently Eyed
While Takeda Pharmaceutical was mum about the specifics of the Specialty Business Unit when its April launch was announced on February 16, gastroenterology drugs are the most likely portfolio that would be pitched by the new division, including Entyvio (vedolizumab)…
To read the full story
Related Article
- Takeda’s Specialty Business Unit Boots Up with Entyvio Detailing
January 25, 2019
- Takeda to Revamp Sales Offices as Japan Shifts to Community-Based Care System
February 20, 2018
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- SanBio Eyes October Start for Akuugo Treatment
September 18, 2026
- Toho Unit to Launch Pharma-Wholesaler Payment Service
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





